Jorge L Salinas1, Chelsea G Major2, Daniel M Pastula3, Emilio Dirlikov4, Ashley Styczynski5, Carlos A Luciano6, Valerie Wojna6, Tyler M Sharp7, James J Sejvar7, Brenda Rivera-Garcia8. 1. Epidemic Intelligence Service, CDC, Atlanta, Georgia. Electronic address: jsalinas@cdc.gov. 2. Office for State, Tribal, Local, and Territorial Support, CDC, Atlanta, Georgia. 3. National Center for Emerging and Zoonotic Infectious Diseases, CDC, Atlanta, Georgia; University of Colorado Denver, Aurora, CO, United States. 4. Epidemic Intelligence Service, CDC, Atlanta, Georgia; Puerto Rico Department of Health, San Juan, Puerto Rico. 5. Epidemic Intelligence Service, CDC, Atlanta, Georgia. 6. University of Puerto Rico, San Juan, Puerto Rico. 7. National Center for Emerging and Zoonotic Infectious Diseases, CDC, Atlanta, Georgia. 8. Puerto Rico Department of Health, San Juan, Puerto Rico.
Abstract
BACKGROUND: Zika virus has been associated with increases in Guillain-Barré syndrome (GBS) incidence. A GBS incidence estimation and clinical description was performed to assess baseline GBS epidemiology before the introduction of Zika virus in Puerto Rico. METHODS: Hospitalization administrative data from an island-wide insurance claims database and U.S. Census Bureau population estimates provided a crude GBS incidence for 2013. This estimate was adjusted using the proportion of GBS cases meeting Brighton criteria for confirmed GBS from nine reference hospitals. Characteristics of confirmed GBS cases in the same nine hospitals during 2012-2015 are described. RESULTS: A total of 136 GBS hospitalization claims were filed in 2013 (crude GBS incidence was 3.8 per 100,000 population). The adjusted GBS incidence was 1.7 per 100,000 population. Of 67 confirmed GBS cases during 2012-2015, 66% had an antecedent illness. Median time from antecedent illness to GBS onset was 7days. Most cases (67%) occurred during July-September. CONCLUSIONS: Puerto Rico's GBS incidence for 2013 was estimated using a combination of administrative data and medical records review; this method could be employed in other regions to monitor GBS incidence before and after the introduction of GBS infectious triggers. Published by Elsevier B.V.
BACKGROUND:Zika virus has been associated with increases in Guillain-Barré syndrome (GBS) incidence. A GBS incidence estimation and clinical description was performed to assess baseline GBS epidemiology before the introduction of Zika virus in Puerto Rico. METHODS: Hospitalization administrative data from an island-wide insurance claims database and U.S. Census Bureau population estimates provided a crude GBS incidence for 2013. This estimate was adjusted using the proportion of GBS cases meeting Brighton criteria for confirmed GBS from nine reference hospitals. Characteristics of confirmed GBS cases in the same nine hospitals during 2012-2015 are described. RESULTS: A total of 136 GBS hospitalization claims were filed in 2013 (crude GBS incidence was 3.8 per 100,000 population). The adjusted GBS incidence was 1.7 per 100,000 population. Of 67 confirmed GBS cases during 2012-2015, 66% had an antecedent illness. Median time from antecedent illness to GBS onset was 7days. Most cases (67%) occurred during July-September. CONCLUSIONS: Puerto Rico's GBS incidence for 2013 was estimated using a combination of administrative data and medical records review; this method could be employed in other regions to monitor GBS incidence before and after the introduction of GBS infectious triggers. Published by Elsevier B.V.
Entities:
Keywords:
Guillain-Barré syndrome; Incidence; Intravenous immunoglobulin; Polyneuropathy; Puerto Rico
Authors: Chelsea G Major; Emilio Dirlikov; Nicole A Medina; Roberta Lugo-Robles; Desiree Matos; Jorge Muñoz-Jordán; Candimar Colón-Sánchez; Myriam García-Negrón; Marangely Olivero-Segarra; Graciela Malavé-González; Dana L Thomas; Carlos A Luciano; Stephen H Waterman; James Sejvar; Tyler M Sharp; Brenda Rivera-García Journal: P R Health Sci J Date: 2018-12 Impact factor: 0.705
Authors: Emilio Dirlikov; Chelsea G Major; Nicole A Medina; Roberta Lugo-Robles; Desiree Matos; Jorge L Muñoz-Jordan; Candimar Colon-Sanchez; Myriam Garcia; Marangely Olivero-Segarra; Graciela Malave; Gloria M Rodríguez-Vega; Dana L Thomas; Stephen H Waterman; James J Sejvar; Carlos A Luciano; Tyler M Sharp; Brenda Rivera-García Journal: JAMA Neurol Date: 2018-09-01 Impact factor: 18.302
Authors: Emilio Dirlikov; José V Torres; Roosecelis Brasil Martines; Sarah Reagan-Steiner; George Venero Pérez; Aidsa Rivera; Chelsea Major; Desiree Matos; Jorge Muñoz-Jordan; Wun-Ju Shieh; Sherif R Zaki; Tyler M Sharp Journal: Emerg Infect Dis Date: 2018-01 Impact factor: 6.883
Authors: Jussara R Angelo; Trevon L Fuller; Bianca B S Leandro; Heitor L F Praça; Renata D Marques; João M C Ferreira; Camila C B Pupe; Olívia C Perez; Karin Nielsen-Saines; Osvaldo J M Nascimento; Paulo C Sabroza Journal: Int J Gynaecol Obstet Date: 2020-01 Impact factor: 3.561